KLOW Peptide Blend: What Is In It and What Each Component Is Studied For

KLOW is a supplied combination of four separate research peptides rather than a single molecule. Because it is a blend, evaluating it means evaluating each component independently — the literature on the mixture as a mixture is essentially non-existent, and any assessment has to be assembled from the individual compounds.

The four components

A KLOW blend combines BPC-157, TB-500 (a thymosin β4 fragment), GHK-Cu and KPV. They come from four unrelated peptide families and act through unrelated mechanisms, which is worth stating plainly: this is a co-formulation, not a designed multi-target molecule of the kind seen in incretin research.

BPC-157

A synthetic 15-amino-acid sequence derived from a fragment of human gastric juice protein BPC. The published work is overwhelmingly rodent, and much of it originates from a small number of research groups. Reported mechanisms in those models centre on nitric oxide signalling and on growth-factor receptor pathways. The indexed literature is available via PubMed.

TB-500

TB-500 is not thymosin β4 itself but a synthetic fragment corresponding to its actin-binding region. Thymosin β4 is a 43-residue G-actin sequestering protein, and the actin-binding motif is the part most studied in cell-migration assays. See the thymosin β4 literature.

GHK-Cu

A tripeptide (glycyl-L-histidyl-L-lysine) that forms a coordination complex with copper(II). The copper is not incidental — the peptide’s studied activity in fibroblast culture is tied to the complex rather than the free tripeptide. Literature: PubMed.

KPV

The C-terminal tripeptide of α-melanocyte-stimulating hormone (lysine-proline-valine). It has been examined in cell and rodent models of intestinal inflammation, generally as a melanocortin-pathway fragment that retains some activity without full receptor agonism. Literature: PubMed.

Why a blend complicates analysis

Four peptides in one vial creates two practical problems for a laboratory. The first is analytical: a purity figure for a blend is not a single number. Each component has its own retention time on RP-HPLC and its own mass, and a certificate has to resolve all four rather than reporting one aggregate peak. The second is experimental: any observed effect in a model system cannot be attributed to one component without running the components separately as controls.

For that reason, researchers designing component-level experiments generally source the individual peptides — BPC-157 and TB-500 and copper peptides are stocked separately — and reserve blends for work where the combination itself is the variable under study.

Net peptide content in a blend

An 80mg blend figure refers to total peptide across all four components, not 80mg of each. Anyone calculating concentrations for a specific component needs the per-component breakdown, and gross peptide weight is not the same as net peptide content once counter-ions and residual water are accounted for. That distinction is covered in more depth in our note on net peptide content.

Further reading

Each component above links to its indexed literature on PubMed. Certificates of analysis for the compounds we supply are published on this site; see how to read a certificate of analysis for guidance on interpreting them.

ExoLabz supplies compounds for laboratory research use only. Nothing on this page is medical advice or a suggestion of human or veterinary use. Certificates of analysis for each compound are published on this site.

What is in KLOW, and in GLOW

Both are supplied combinations rather than single molecules, and the per-component masses are the whole story:

• KLOW 80 mg — BPC-157 10 mg, TB-500 10 mg, GHK-Cu 50 mg, KPV 10 mg
• GLOW 70 mg — BPC-157 10 mg, TB-500 10 mg, GHK-Cu 50 mg

So GLOW is KLOW without the KPV, and in both cases GHK-Cu is more than half the total mass. That matters when comparing a blend against a single-compound vial: an 80 mg total sounds large next to a 10 mg vial, but only 10 of those milligrams are BPC-157. Price per milligram of the component you actually care about is the comparison that means something — see what cost per milligram hides.

The four components are four different kinds of molecule

This is the part most descriptions skip. These are not four variations on a theme; they belong to different chemical classes with different analytical behaviour.

BPC-157 is a pentadecapeptide, GEPPPGKPADDAGLV, C62H98N16O22, about 1,419.5 g/mol, CAS 137525-51-0. Three consecutive prolines in the middle of the chain broaden its peak on reverse-phase HPLC, because the bond preceding each proline interconverts between cis and trans conformations slowly relative to the run. A broad or shouldered peak here is a property of the molecule, not evidence of a second substance.

TB-500 is not thymosin beta-4. It is the short acetylated fragment corresponding to the thymosin beta-4 17–23 region — seven residues, C38H68N10O14, about 889 g/mol, CAS 885340-08-9 — whereas full-length thymosin beta-4 is a 43-residue protein of roughly 4,963 g/mol. The mass on the certificate is what separates them. See thymosin beta-4 versus the TB-500 fragment.

GHK-Cu is a metal complex, not a plain peptide: the GHK tripeptide coordinated to copper(II), C14H23CuN6O4, about 402.92 g/mol, CAS 89030-95-5. The free tripeptide is a different substance with a different registry number, 49557-75-7, and a mass roughly 62 Da lower. See GHK-Cu and copper coordination.

KPV is a tripeptide, Lys-Pro-Val, C16H30N4O4, 342.43 g/mol, CAS 67727-97-3 — the C-terminal tripeptide of alpha-MSH. It is present only in KLOW. Note that a search for “KPV” in a chemical database will also return an unrelated small molecule; the tripeptide is the one identified by that CAS number.

Why a four-component blend is harder to characterise

A single-compound certificate reports one purity figure against one target mass. A blend has to account for each component separately, and that raises problems a single vial does not have.

• Co-elution. Components with similar hydrophobicity overlap on a reverse-phase column. In KLOW the two tripeptide-scale species and the two larger peptides sit far enough apart to resolve, but the trace is inherently busier than a single compound’s, and reading it needs the method conditions.
• Ratio verification is a separate measurement. Establishing that each component is pure is not the same as establishing that the vial contains the stated ratio. The second is quantitative and is not what a purity percentage reports.
• Mixed stability. The components do not degrade at the same rate. Copper is redox active, so GHK-Cu is the most condition-sensitive thing in the vial; BPC-157 and KPV are comparatively robust. The blend’s practical shelf life is set by its least stable component, not by its average.
• No attribution. If a result looks anomalous, a blend gives you no way to attribute it to one component. For work where that matters, single vials combined at the bench are the better tool — the blend is a convenience, and the convenience costs you the ability to isolate a variable.

See reading an HPLC chromatogram and where peptide impurities come from.

What the copper content implies for handling

Because GHK-Cu is more than half of both blends by mass, the handling requirement is effectively GHK-Cu’s requirement. Copper complexes have a visible absorption band, which is why the material is blue rather than white — colour is a crude but real indicator, and an off-colour or patchy cake is worth photographing on arrival. Copper is also redox active, which makes the complex more sensitive to light, oxygen and warmth than a plain tripeptide would be.

Store lyophilised, refrigerated, in the dark, and let a closed vial reach room temperature before opening so atmospheric moisture condenses on the glass rather than on the powder. See how peptides degrade and what to check when a shipment arrives.

Reading a certificate for a blend

Four questions make a blend certificate usable, and they are not the same four you would ask of a single compound:

• Is each component identified by mass, not only named? Four names and one purity figure is not an identification.
• Is the stated composition per component, in milligrams, rather than a total?
• Is the detection wavelength given? Purity at 214 nm and at 280 nm are not comparable, and the components here differ in aromatic content — so wavelength choice changes the apparent ratio.
• Can the batch be tied to the vial in your hand? ExoLabz certificates carry photographs of the batch, and vials are matched by cap and crimp colour rather than by a printed batch number.

See how to read a certificate of analysis and net peptide content — for a blend, net content applies per component, which is the point most easily missed.